Key result
Current management of antenatal VTE with predominantly low molecular weight heparin was effective and safe, resulting in 0 recurrent events and no increase in postpartum haemorrhage.
Observational (n=126)
Yes
Current diverse management of antenatal VTE with LMWH appears safe and effective, questioning the need for twice-daily dosing and routine anti-Xa monitoring.
Authors
No takes yet. Share an insight, caveat, or question.
Supports LMWH-based antenatal VTE management in practice; leaves open optimal dosing frequency and anti-Xa monitoring needs.
Voke et al. (2007) conducted an observational in Antenatal venous thromboembolism (n=126). Current management of antenatal VTE (predominantly LMWH) was evaluated on Recurrent events and postpartum haemorrhage. Current management of antenatal VTE with predominantly low molecular weight heparin was effective and safe, resulting in 0 recurrent events and no increase in postpartum haemorrhage.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: